| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050579506 |
| P356 | DOI | 10.1007/S11912-013-0321-9 |
| P698 | PubMed publication ID | 23690089 |
| P5875 | ResearchGate publication ID | 236924294 |
| P2093 | author name string | Lisa L Wang | |
| Jason T Yustein | |||
| Nino Rainusso | |||
| P2860 | cites work | Addition of pamidronate to chemotherapy for the treatment of osteosarcoma | Q24594269 |
| Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells | Q28307320 | ||
| Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial | Q33340568 | ||
| Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. | Q33373879 | ||
| Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma | Q33379627 | ||
| Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience | Q33385564 | ||
| R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study | Q33397796 | ||
| Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group | Q33398810 | ||
| Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. | Q33399884 | ||
| Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma. | Q33404428 | ||
| Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program | Q33406382 | ||
| Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients | Q77302606 | ||
| Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols | Q77579162 | ||
| Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999 | Q77783931 | ||
| Is Ewing's sarcoma a stem cell tumor? | Q80969232 | ||
| Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital | Q83176936 | ||
| Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution | Q87415291 | ||
| Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. | Q33713042 | ||
| The increasing complexity of the cancer stem cell paradigm | Q33862363 | ||
| Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. | Q33943320 | ||
| Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients | Q33953723 | ||
| Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma | Q34155816 | ||
| Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection | Q34166288 | ||
| EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model | Q34206278 | ||
| Current therapeutic approaches in metastatic and recurrent ewing sarcoma | Q34373180 | ||
| Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. | Q34404179 | ||
| Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. | Q34532932 | ||
| FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo | Q34575984 | ||
| Osteosarcoma. | Q34617440 | ||
| Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years | Q34627906 | ||
| Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. | Q34638074 | ||
| The genetics of osteosarcoma | Q34639086 | ||
| Oncogenic fusion protein EWS/FLI1 down-regulates gene expression by both transcriptional and posttranscriptional mechanisms | Q35067662 | ||
| Treatment of Ewing sarcoma family of tumors: current status and outlook for the future | Q35090650 | ||
| Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program | Q35186275 | ||
| Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma | Q35609719 | ||
| A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis | Q35665048 | ||
| Role of radiotherapy in Ewing tumors | Q35719663 | ||
| The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting | Q35832365 | ||
| Biology and therapeutic advances for pediatric osteosarcoma | Q35841976 | ||
| Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement | Q35848291 | ||
| Experimental evidence for a neural origin of Ewing's sarcoma of bone | Q35856430 | ||
| PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma | Q35871546 | ||
| Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group | Q36097717 | ||
| Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group | Q36389207 | ||
| Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program | Q36392660 | ||
| Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas | Q36551839 | ||
| Second cancers in patients with the Ewing sarcoma family of tumours | Q36711750 | ||
| Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies | Q36849432 | ||
| Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma | Q37026245 | ||
| Notch signaling contributes to the pathogenesis of human osteosarcomas | Q37323322 | ||
| A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma | Q37421771 | ||
| Ewing's sarcoma: standard and experimental treatment options | Q37522056 | ||
| International collaboration is feasible in trials for rare conditions: the EURAMOS experience | Q37705068 | ||
| Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? | Q37894250 | ||
| Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. | Q37954566 | ||
| The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma | Q38046209 | ||
| A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs | Q38334606 | ||
| Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma | Q38338166 | ||
| Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma. | Q39314094 | ||
| A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma | Q39331421 | ||
| Critical role of notch signaling in osteosarcoma invasion and metastasis | Q39352960 | ||
| Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma | Q39427542 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts | Q39562583 | ||
| Excellent prognosis in a subset of patients with Ewing sarcoma identified at diagnosis by CD56 using flow cytometry. | Q39564068 | ||
| Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models | Q39579355 | ||
| Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma | Q39584417 | ||
| Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells | Q39589480 | ||
| Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling | Q39600616 | ||
| Nutlin-3a is a potential therapeutic for ewing sarcoma | Q39628701 | ||
| Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients | Q39655936 | ||
| NVP-BEZ235 as a new therapeutic option for sarcomas. | Q39752874 | ||
| Genetically defined EWS/FLI1 model system suggests mesenchymal origin of Ewing's family tumors | Q39931953 | ||
| Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. | Q40318247 | ||
| The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis | Q40602468 | ||
| Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli | Q40628011 | ||
| Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement | Q40640520 | ||
| Targeting the p53 Pathway in Ewing Sarcoma. | Q41303735 | ||
| High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. | Q43626751 | ||
| Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone | Q44320806 | ||
| Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival | Q45858205 | ||
| Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. | Q46051674 | ||
| A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. | Q51496900 | ||
| Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. | Q51730708 | ||
| Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma. | Q53167841 | ||
| EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. | Q53487773 | ||
| The Biology of Ewing sarcoma. | Q53575285 | ||
| Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report | Q57008750 | ||
| Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs | Q57339791 | ||
| Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study | Q64211541 | ||
| Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience | Q67530667 | ||
| Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group | Q71975310 | ||
| P433 | issue | 4 | |
| P921 | main subject | teenager | Q1492760 |
| P304 | page(s) | 296-307 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Current Oncology Reports | Q2264969 |
| P1476 | title | The adolescent and young adult with cancer: state of the art -- bone tumors | |
| P478 | volume | 15 |
| Q53714815 | ATF4 regulated by MYC has an important function in anoikis resistance in human osteosarcoma cells. |
| Q36301216 | Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma |
| Q27009541 | Adoptive cell therapy for sarcoma |
| Q37071040 | Alteration of WWOX in human cancer: a clinical view. |
| Q38220804 | Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology |
| Q38726635 | Foscan and foslip based photodynamic therapy in osteosarcoma in vitro and in intratibial mouse models |
| Q38783819 | H19 Functions as a ceRNA in Promoting Metastasis Through Decreasing miR-200s Activity in Osteosarcoma |
| Q38709198 | Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells. |
| Q39427334 | How PET/MR Can Add Value For Children With Cancer |
| Q92034918 | Incidence and mortality of bone cancer among children, adolescents and young adults of Brazil |
| Q87839020 | Knockdown of Long Noncoding RNA TUG1 Inhibits the Proliferation and Cellular Invasion of Osteosarcoma Cells by Sponging miR-153 |
| Q36750689 | Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis |
| Q38741167 | MicroRNA-124 upregulation inhibits proliferation and invasion of osteosarcoma cells by targeting sphingosine kinase 1. |
| Q38836625 | MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma cell lines possibly by targeting Sox4. |
| Q92382349 | MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2 |
| Q38867232 | MicroRNA-196a overexpression promotes cell proliferation and inhibits cell apoptosis through PTEN/Akt/FOXO1 pathway. |
| Q36944910 | MicroRNA-224 promotes the sensitivity of osteosarcoma cells to cisplatin by targeting Rac1. |
| Q50853847 | MicroRNA-342-3p Inhibits the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting Astrocyte-Elevated Gene-1 (AEG-1). |
| Q91973078 | MicroRNA-509-3p inhibits cellular migration, invasion, and proliferation, and sensitizes osteosarcoma to cisplatin |
| Q49422936 | PAK5 overexpression is associated with lung metastasis in osteosarcoma |
| Q37641546 | PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity |
| Q49831544 | Paeoniflorin induces G2/M cell cycle arrest and caspase-dependent apoptosis through the upregulation of Bcl-2 X-associated protein and downregulation of B-cell lymphoma 2 in human osteosarcoma cells |
| Q38198116 | Proteomics of osteosarcoma. |
| Q38721643 | RASSF4 Overexpression Inhibits the Proliferation, Invasion, EMT, and Wnt Signaling Pathway in Osteosarcoma Cells |
| Q35535148 | Retracted: MicroRNA-33b Suppresses Migration and Invasion by Targeting c-Myc in Osteosarcoma Cells |
| Q34764403 | Retracted: MicroRNA-503 Acts as a Tumor Suppressor in Osteosarcoma by Targeting L1CAM |
| Q35602148 | S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications |
| Q30827937 | Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential |
| Q41413210 | Serum microRNA-17 functions as a prognostic biomarker in osteosarcoma |
| Q35601012 | Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells |
| Q88619014 | Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma |
| Q47107018 | Tetrahydrocurcumin induces mesenchymal-epithelial transition and suppresses angiogenesis by targeting HIF-1α and autophagy in human osteosarcoma |
| Q38451770 | The immunotherapy of canine osteosarcoma: a historical and systematic review |
| Q38928368 | The tumor suppressor role of PAQR3 in osteosarcoma |
| Q36356334 | ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib |
| Q34430382 | p21-activated kinase 7 is an oncogene in human osteosarcoma |
Search more.